Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Straumann Holding AGXSWX:STMN +0.60%94 Future 3-5Y EPS without NRI Growth Rate is 13.64 as of Sep. 08, 2026. GuruFocus rates XSWX:STMN with a GF Score™ of 94/100 and a GF Value™ of CHF126.07 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 282 Medical Devices & Instruments companies, Straumann Holding AG ranks worse than 67.73% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Straumann Holding AG's Future 3-5Y EPS without NRI Growth Rate is 13.64.
Straumann Holding AG (XSWX:STMN) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Straumann Holding AG Future 3-5Y EPS without NRI Growth Rate Related Terms
XSWX:STMN vs ISRG, BDX, RMD: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 13.64 mean?
Straumann Holding AG (XSWX:STMN) has a Future 3-5Y EPS without NRI Growth Rate of 13.64 as of Sep. 08, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Straumann Holding AG and its competitors. According to the industry distribution chart, Straumann Holding AG ranks #191 out of 282 companies in the Medical Devices & Instruments industry, placing it in the top 67.7%.
Is Straumann Holding AG's Future 3-5Y EPS without NRI Growth Rate too high?
Straumann Holding AG's current Future 3-5Y EPS without NRI Growth Rate is 13.64. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.70. Straumann Holding AG's value of 13.64 is 34.1% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #191 out of 282 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Future 3-5Y EPS without NRI Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #191 out of 282 companies for Future 3-5Y EPS without NRI Growth Rate. This places Straumann Holding AG in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.70. Straumann Holding AG's value of 13.64 is 34.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.70, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Future 3-5Y EPS without NRI Growth Rate of 13.64 is 34.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Future 3-5Y EPS without NRI Growth Rate is 13.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF126.07, compared to a current price of CHF93.58 — trading 25.8% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 13.64 and 34.1% below the Medical Devices & Instruments industry median of 20.70. Straumann Holding AG's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Future 3-5Y EPS without NRI Growth Rate is 13.64 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF93.58 is trading 25.8% below its estimated GF Value™ of CHF126.07.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Future 3-5Y EPS without NRI Growth Rate: 13.64
GF Value™: CHF126.07 vs. price of CHF93.58 (25.8% below fair value)
Industry Position: 34.1% below the Medical Devices & Instruments median (#191 of 282)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
94GF Score
Get the complete analysis for XSWX:STMN
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
